Eli Lilly Updates Spondyloarthritis Trial Data and Long-Term Rheumatoid Arthritis Studies

Eli Lilly and Company presented positive data from two Phase III clinical trials at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Chicago yesterday. The data is related to the company’s Taltz (ixekizumab) in differing populations of patients with radiographic axial spondyloarthritis (asxSpA).